Hostname: page-component-7c8c6479df-p566r Total loading time: 0 Render date: 2024-03-28T17:37:31.033Z Has data issue: false hasContentIssue false

Gut hormones and the treatment of disease cachexia

Nutrition Society and BAPEN Medical Symposium on ‘Nutrition support in cancer therapy’

Published online by Cambridge University Press:  01 May 2008

Damien Ashby*
Affiliation:
Metabolic Medicine, Imperial College, Hammersmith Hospital Campus, Du Cane Road, LondonW12 0NN, UK
Peter Choi
Affiliation:
Kidney and Transplant Institute, Imperial College, London, UK
Stephen Bloom
Affiliation:
Metabolic Medicine, Imperial College, Hammersmith Hospital Campus, Du Cane Road, LondonW12 0NN, UK
*
*Corresponding author: Dr Damien Ashby, fax +44 20 8383 3242, email d.ashby@imperial.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Advances in the understanding of appetite are leading to a refined concept of disease cachexia and point to novel therapeutic strategies based on the manipulation of appetite. The complex social and psychological short-term influences on appetite obscure the fact that over the longer term appetite is tightly regulated by physiological considerations; the homeostatic control of energy balance. Like obesity, which is now viewed as a disorder of homeostasis, cachexia can be seen as an adaptive response to the disease state that becomes harmful when prolonged. Several lines of evidence implicate a disorder of appetite regulation in the pathogenesis of cachexia. As the only known circulating mediator of increased appetite the peptide hormone ghrelin has attracted attention as a potential therapy. Trials in patients with various chronic illnesses, including cancer and kidney failure, have demonstrated short-term increases in energy intake. Trials in patients with emphysema and heart failure have also shown benefits in clinical outcomes such as lean body mass and exercise capacity, and longer-term trials using oral analogues are being undertaken. As well as improving nutrition, ghrelin has a number of other actions that may be useful, including an anti-inflammatory effect; of interest since many cachexias are associated with inappropriate immune activation. The manipulation of appetite, in particular by ghrelin agonism, is emerging as an exciting potential therapy for disease cachexia. Future research should focus on the ascertainment of clinically-relevant outcomes, and further characterisation of the non-nutritional effects of this pathway.

Type
Research Article
Copyright
Copyright © The Authors 2008

Advances in the understanding of energy homeostasis have led to the realisation that a number of conditions are caused by a disorder of appetite regulation. Many gut hormones are circulating mediators of appetite control and can be used therapeutically to manipulate appetite. This developing field, which is largely driven by the need to understand obesity, is also of relevance to cachexia, which as a result is undergoing a change in concept from unavoidable symptom to treatable complication.

Cachexia

Cachexia refers to the decline in nutritional state that is a common feature of many chronic diseases, including cancer, heart failure and chronic kidney disease. It involves the loss of both the fat and protein stores (the latter coming largely from skeletal muscle) leading to weight loss and weakness, and even at an early stage it is associated with increased mortality. Although the hallmark of cachexia is weight loss, this outcome may be difficult to detect in the early stages or may be masked by other factors such as fluid retention, but cachexia can be said to exist when there is a persistent state of negative energy or protein balance. It therefore becomes most apparent as the disease progresses and is often thought to be a feature of ‘end-stage’ disease. However, in reality it has been present since very early in the patient's illness and may have been amongst the presenting features when the disease was first diagnosed. Chronic kidney disease is no exception, with cachexia beginning early and progressing along with the decline in function of the kidneys. It is most evident therefore in those requiring dialysis treatment and becomes more common with increasing duration on dialysis(Reference Chazot, Laurent, Charra, Blanc, VoVan, Jean, Vanel, Terrat and Ruffet1Reference O'Sullivan, Lawson, Chan and Kelly4).

Cachexia in chronic diseases has profound survival implications. In relation to kidney disease, studies of patients treated in French dialysis units in the 1970s first revealed a link between poor nutritional state and mortality(Reference Degoulet, Legrain, Reach, Aime, Devries, Rojas and Jacobs5), and since then a number of large studies have confirmed higher mortality associated with low albumin, low BMI or low creatinine(Reference Leavey, McCullough, Hecking, Goodkin, Port and Young6Reference Port, Ashby, Dhingra, Roys and Wolfe8). This link has been confirmed with a wide variety of indicators of energy balance, including appetite, protein intake and energy expenditure(Reference Kalantar-Zadeh, Block, McAllister, Humphreys and Kopple9Reference Wang, Sea, Tang, Sanderson, Lui, Li and Woo11), as well as specialised measures of body composition including bioimpedance analysis and dual-energy X-ray absorption(Reference Kakiya, Shoji and Tsujimoto12, Reference Maggiore, Nigrelli, Ciccarelli, Grimaldi, Rossi and Michelassi13). Baseline levels of biochemical variables such as albumin and cholesterol are the most powerful prognostic indicators in patients undergoing dialysis and have been shown to predict survival far in advance, with follow-up periods in some studies as long as 10 years(Reference Avram, Sreedhara, Fein, Oo, Chattopadhyay and Mittman14, Reference Mittman, Avram, Oo and Chattopadhyay15).

Poor nutrition has also been found to predict high mortality in other chronic illnesses. Weight loss or low BMI are poor prognostic factors in heart failure(Reference Davos, Doehner, Rauchhaus, Cicoira, Francis, Coats, Clark and Anker16Reference Freeman and Roubenoff21), emphysema(Reference Landbo, Prescott, Lange, Vestbo and Almdal22Reference Chailleux, Laaban and Veale24), cirrhosis of the liver(Reference Alberino, Gatta, Amodio, Merkel, Di Pascoli, Boffo and Caregaro25) and rheumatoid arthritis(Reference Escalante, Haas and del Rincon26, Reference Kremers, Nicola, Crowson, Ballman and Gabriel27). Similar findings have been made in many cancers(Reference Di Fiore, Lecleire, Pop, Rigal, Hamidou, Paillot, Ducrotté, Lerebours and Michel28Reference DeWys, Begg and Lavin32), with the possible exception of breast cancer, for which low BMI is not associated with increased mortality, unlike low albumin(Reference Whiteman, Hillis, Curtis, McDonald, Wingo and Marchbanks33, Reference Lis, Grutsch, Vashi and Lammersfeld34).

The fact that nutritional indices predict mortality far in advance, independent of and better than other prognostic variables, suggests that cachexia in itself has a detrimental effect on survival. It is therefore not merely a symptom with no importance beyond being unpleasant for patients, but a complication with its own adverse outcomes and a legitimate object of life-prolonging (as opposed to palliative) treatment. Although obvious, this issue is important, since it is frequently doubted or overlooked by clinicians. Evidence resolving this issue is lacking however; the question of whether a sustained improvement in nutritional state alone leads to a survival benefit would be best addressed with interventional studies, but for the most part remains unanswered because of the difficulty of achieving sustained nutritional improvement.

The cause of malnutrition in these conditions is poorly understood. Energy expenditure has been found to be increased by most investigators and there is sometimes a small quantity of abnormal nutrient loss, e.g. during the dialysis procedure, but the predominant finding is of reduced appetite. Occasionally this anorexia is a result of secondary complications that are known to influence appetite such as gastritis or a concurrent infection, but for the most part the reduction in appetite occurs when no reversible factor can be identified. The frequent observation of increased levels of inflammatory cytokines in the plasma has led some investigators to the conclusion that cachexia is caused by inflammation, and the pathogenesis of cachexia and inflammation are undoubtedly linked(Reference Stenvinkel, Heimburger, Paultre, Diczfalusy, Wang, Berglund and Jogestrand35). However, the predominant direction of this association is far from clear and neither mechanism is well understood.

Cachexia therefore appears to be an intrinsic part of the primary disease, for which the pathogenesis is unclear. In order to understand this process it is necessary to focus on appetite and how it is normally regulated, because despite the influence of numerous external factors appetite is surprisingly tightly controlled.

Appetite

Like the fact that objects fall to the ground, the fact that man has the desire to eat is such a fundamental part of his existence that it is sometimes difficult to appreciate the underlying mechanism.

In the short term, appetite depends on an enormous number of factors, which doubtless include the body's need for energy but more frequently are dominated by other considerations: ‘this food is really nice, but I should leave some for my friend, plus I want to look good on the beach this summer, although it is still only February …’ ‘Which is most important right now?’ It appears to be a choice that is dependent on values and personality.

However, the long-term picture is quite different, and this position can be appreciated with a simple calculation. Although body weight tends to increase slightly during much of adult life, it is remarkable for its stability, with a yearly weight change of <1 kg in most of the population(Reference Brown, Williams, Ford, Ball and Dobson36). The excess energy needed to induce this weight gain has been variably estimated, but is approximately 30 MJ(Reference Diaz, Prentice, Goldberg, Murgatroyd and Coward37), whilst the yearly energy intake is >3000 MJ. Consequently, most individuals manage to match energy intake to equal energy expenditure, with an error of <1%. It was long suspected, therefore, that a regulatory system existed to control appetite in order to maintain energy homeostasis(Reference Weigle38), and this theory was confirmed by the subsequent discovery of some of the elements of this system, beginning with the discovery of the adipose tissue hormone leptin(Reference Zhang, Proenca, Maffei, Barone, Leopold and Friedman39), which gives feedback to the brain about the adequacy of energy stored in the form of fat. Obesity is now firmly accepted to be a disorder of this homeostatic system.

That energy balance is homeostatically controlled suggests that cachexia, as another condition in which energy is imbalanced, is also a disorder of this homeostatic system. If an external factor arises that influences appetite or energy expenditure in some way, then the regulatory system should adjust to restore energy balance. A persistent state of imbalance is maintained when the system itself is disordered or adjusted.

This outcome explains the difficulty encountered in increasing long-term energy intake in clinical trials, which is seen even when energy supplements are administered parenterally. For example, in a randomised trial of intradialytic parenteral nutrition in patients undergoing haemodialysis both groups received an oral supplement, but the intervention group also received an intravenous supplement of approximately 25 kJ/kg at each dialysis session (three times per week) for 12 months. Modest improvements in albumin and body weight were found for both groups, but no benefit in clinical outcomes and no differences between the two groups. One striking finding was that spontaneous energy intake (i.e. what the patients were eating at home between dialysis sessions) gradually declined over the first 6 months of the trial in both groups, and even more so in the intervention group, so that the total energy intake was found to be little changed in either group during most of the trial(Reference Cano, Fouque and Roth40). To compensate for the supplements being taken appetite was subconsciously being down-regulated, restoring the total energy intake to its previous level.

It has thus far been reasoned on theoretical grounds that cachexia is likely to be a result of some change in appetite regulation, but no direct evidence has been considered. However, different lines of evidence are beginning to emerge that firmly implicate appetite control in the pathophysiology of cachexia.

First, human observational studies have suggested that negative regulators of appetite are elevated in cachexia. Most attention has focused on leptin, which is higher than expected in heart failure(Reference Schulze, Kratzsch, Linke, Schoene, Adams, Gielen, Erbs, Moebius-Winkler and Schuler41, Reference Doehner, Pflaum and Rauchhaus42) as well as in chronic kidney disease(Reference Heimburger, Lonnqvist, Danielsson, Nordenstrom and Stenvinkel43, Reference Howard, Lord, Clutterbuck, Ghatei, Pusey and Bloom44), although other hormones are also involved, such as peptide YY, which is also elevated in these conditions(Reference le Roux, Ghatei, Gibbs and Bloom45). Although many of these studies are merely highlighting a cross-sectional association, longitudinal studies have also shown that raised baseline leptin predicts weight loss over the next 17 months in patients undergoing dialysis, strengthening the likelihood that this association is indeed causal(Reference Odamaki, Furuya, Yoneyama, Nishikino, Hibi, Miyaji and Kumagai46).

Second, a number of animal studies have shown prevention or reversal of cachexia by deletion or blockade of specific appetite pathways. For example, in the melanocortin-4 receptor-knock-out mouse, which lacks a key part of the brain's appetite circuitry(Reference Marks, Ling and Cone47), the cachexia that usually follows the induction of kidney failure or cancer is much reduced. Also, the induction of kidney failure, which causes loss of both lean and fat mass in normal mice, induces very little change in body weight in leptin receptor-deficient mice(Reference Cheung, Yu, Little, Cone, Marks and Mak48). In addition, injection of a melanocortin antagonist into the brain, which therefore blocks part of the appetite circuit, reverses the weight loss in cancer-bearing mice(Reference Wisse, Frayo, Schwartz and Cummings49), and in other experiments the loss of appetite and lean body mass are prevented by peripheral injection of similar agents(Reference Markison, Foster, Chen, Brookhart, Hesse, Hoare, Fleck, Brown and Marks50, Reference Nicholson, Kohler, Schaerer, Senn, Weyermann and Hofbauer51).

Cachexia therefore appears to be a result of an adaptation of appetite to the diseased state. However, if reduced appetite in these conditions has such adverse consequences, then why should such an adaptive mechanism exist? Although speculative, the answer is perhaps obvious when it is considered that short-term illnesses are a more powerful evolutionary pressure than modern chronic diseases, which occur largely in later life. During a short-term illness such as an infection or injury it would be advantageous for appetite to be diminished, so that food-seeking behaviours, e.g. hunting, that would be more hazardous than usual are postponed until after recovery from the illness. Reduced appetite and cachexia may well be consequences of an adaptive mechanism that is of no advantage in the modern setting.

Ghrelin

Ghrelin is a gut hormone involved in appetite regulation that has attracted attention as a possible means of increasing appetite in the treatment of cachexia. It will be helpful to review the relevant physiology briefly.

Integration of the peripheral signals controlling appetite takes place within the hypothalamus. For a detailed consideration of appetite control, which is beyond the scope of the present article, excellent reviews are available(Reference Stanley, Wynne, McGowan and Bloom52, Reference Wynne, Stanley, McGowan and Bloom53). Very briefly, there are two types of neurons within the arcuate nucleus (located at the base of the hypothalamus) that have opposing effects on ingestive behaviour and respond differently to a number of circulating hormones (Fig. 1). Neuropeptide Y-releasing neurons are orexigenic (increasing food intake), whereas melanocortin-releasing neurons are anorexigenic. Anorexigenic signals from the periphery include leptin from adipose tissue and a number of satiety signals from the gut that are released following a meal, e.g. peptide YY and oxyntomodulin. The only known orexigenic signal from the periphery is ghrelin.

Fig. 1. Simplified model of homeostatic appetite control. Appetite is largely governed by the opposing actions of two populations of neurons within the hypothalamus: those releasing melanocortin (MC)-stimulating hormone (αMSH), which act via the MC3 and MC4 receptors and reduce appetite; those releasing neuropeptide Y (NPY), which act via the Y1 and Y5 receptors to increase appetite. A number of circulating hormones affect appetite largely through their action on these hypothalamic neurones. Leptin from adipose tissue reduces appetite, whereas ghrelin from the stomach increases appetite. The gastrointestinal tract also releases a number of ‘satiety’ hormones after a meal that, amongst other actions, reduce appetite; these hormones include peptide YY (PYY) and glucagon-like peptide 1 (GLP-1). , Stimulates; …, inhibits.

Ghrelin was originally discovered as the endogenous ligand for a receptor known to cause the release of growth hormone(Reference Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa54), and increased growth hormone after ghrelin injection has been demonstrated in rodents(Reference Date, Murakami, Kojima, Kuroiwa, Matsukura, Kangawa and Nakazato55) and man(Reference Arvat, Di Vito, Broglio, Papotti, Muccioli, Dieguez, Casanueva, Deghenghi, Camanni and Ghigo56). Of greater interest was the subsequent appreciation of its role in appetite generation. Through its action on neuropeptide-releasing neurons in the hypothalamus(Reference Kamegai, Tamura, Shimizu, Ishii, Sugihara and Wakabayashi57Reference Shintani, Ogawa and Ebihara59) ghrelin leads to increased food intake and weight gain in rodents(Reference Tschop, Smiley and Heiman60Reference Wren, Small and Abbott62) and has been shown to increase food intake, as well as the feeling of hunger in healthy volunteers, when given by intravenous infusion or subcutaneously(Reference Wren, Seal, Cohen, Brynes, Frost, Murphy, Dhillo, Ghatei and Bloom63, Reference Druce, Neary, Small, Milton, Monteiro, Patterson, Ghatei and Bloom64).

Levels of ghrelin rise progressively during the day when not eating, reaching a peak before a meal, after which there is an abrupt drop in levels, suggesting a short-term role in the initiation of each meal. In addition, this daily pattern is superimposed on a basal level that is increased following weight loss by dieting, which suggests involvement also in the longer-term regulation of appetite(Reference Cummings, Weigle, Frayo, Breen, Ma, Dellinger and Purnell65, Reference Cummings, Purnell, Frayo, Schmidova, Wisse and Weigle66).

In animal models of disease-induced cachexia ghrelin has been shown to increase food intake and prevent the loss of body weight. This effect has been seen in rats with wasting induced by repeated lipopolysaccharide injections(Reference Hataya, Akamizu, Hosoda, Kanamoto, Moriyama, Kangawa and Nakao67), rats with cardiac cachexia induced by coronary artery ligation(Reference Nagaya, Uematsu and Kojima68) and in rats and mice with tumours(Reference DeBoer, Zhu and Levasseur69, Reference Wang, Andersson, Iresjo, Lonnroth and Lundholm70). A few studies have examined the potential for ghrelin to improve nutritional status in human cachexia.

In a randomised cross-over study of a single dose of ghrelin given by infusion, increased appetite has been demonstrated in patients with metastatic cancer and anorexia and weight loss(Reference Neary, Small, Wren, Lee, Druce, Palmieri, Frost, Ghatei, Coombes and Bloom71). On separate days patients who were unaware of their treatment allocation were given ghrelin or saline (9 g NaCl/l) by infusion after an overnight fast and then served an excessive quantity of a preselected meal. All seven patients increased their energy intake by an average of 31% following ghrelin infusion, and reported greater appreciation of the meal.

A similar study conducted on nine patients with kidney failure treated by peritoneal dialysis has shown a doubling of energy intake immediately following subcutaneous administration and a 27% increase over the first 24 h period(Reference Wynne, Giannitsopoulou, Small, Patterson, Frost, Ghatei, Brown, Bloom and Choi72). Importantly, food intake over the next 48 h period was unchanged, demonstrating the lack of a compensatory underswing.

The longer-term anabolic effects of ghrelin have also been demonstrated in non-randomised studies involving twice daily infusions. In ten patients with heart failure, left ventricular ejection fraction, exercise capacity and lean body mass were all shown to increase after 3 weeks of treatment, whilst no change was observed in a control group of patients hospitalised for diagnostic testing(Reference Nagaya, Moriya, Yasumura, Uematsu, Ono, Shimizu, Ueno, Kitakaze, Miyatake and Kangawa73). The same investigators have reported similar results in seven patients with chronic obstructive pulmonary disease in whom respiratory muscle strength, lean body mass and functional capacity were found to be improved after a 3-week period of treatment(Reference Nagaya, Itoh, Murakami, Oya, Uematsu, Miyatake and Kangawa74).

It seems likely therefore that the acute effect on appetite translates into a medium-term improvement in nutritional state, but ghrelin is thought to possess a number of other actions that are not obviously nutritional and may prove to be relevant to the cachexia of chronic diseases.

Ghrelin lowers blood pressure by vasodilation in rodents and man by an effect that appears to be independent of NO(Reference Lin, Matsumura, Fukuhara, Kagiyama, Fujii and Iida75Reference Okumura, Nagaya, Enomoto, Nakagawa, Oya and Kangawa77), and this process leads to an increase in stroke volume and cardiac output without a marked change in heart rate in healthy volunteers as well as patients with heart failure(Reference Nagaya, Miyatake, Uematsu, Oya, Shimizu, Hosoda, Kojima, Nakanishi, Mori and Kangawa78Reference Enomoto, Nagaya and Uematsu80). This effect may underlie some of the benefit seen after 3 weeks in patients with heart failure(Reference Nagaya, Moriya, Yasumura, Uematsu, Ono, Shimizu, Ueno, Kitakaze, Miyatake and Kangawa73), and might also be particularly useful in heart failure caused by pulmonary hypertension. In a rat model of pulmonary hypertension induced by monocrotaline injection, repeated administration attenuates a number of features of disease, including the increase in right ventricular pressures, myocyte hypertrophy and vascular remodelling(Reference Henriques-Coelho, Roncon-Albuquerque, Lourenco, Baptista, Oliveira, Brandao-Nogueira, Correia-Pinto and Leite-Moreira81).

Ghrelin is also thought to possess an anti-inflammatory effect. Many cells of the immune system have been found to express receptors for ghrelin(Reference Hattori, Saito, Yagyu, Jiang, Kitagawa and Inagaki82) and in vitro experiments have clearly demonstrated that ghrelin suppresses the release of inflammatory cytokines by stimulated monocytes and lymphocytes(Reference Dixit, Schaffer, Pyle, Collins, Sakthivel, Palaniappan, Lillard and Taub83, Reference Li, Gavrila, Liu, Wang, Gunnlaugsson, Stoll, McCormick, Sigmund, Tang and Weintraub84). In vivo studies have confirmed this effect in a number of rodent models of inflammation, including chemically-induced colitis, pancreatitis or arthritis and acute lung injury induced by sepsis(Reference Dembinski, Warzecha, Ceranowicz, Tomaszewska, Stachura, Konturek and Konturek85Reference Wu, Dong, Zhou, Zhang, Marini, Ravikumar and Wang89). Circulating inflammatory markers and histological grade are reduced by ghrelin, as is the overall clinical severity and mortality. These findings are of particular interest since cachexia is frequently accompanied by inappropriate low-grade inflammation.

Finally, vascular calcification has been shown to be reduced by ghrelin in a rodent model induced by excessive vitamin D(Reference Li, Jiang, Zhao, Pan, Cao, Tang and Chang90). This effect is of interest largely to patients undergoing dialysis in whom vascular calcification commonly accompanies cachexia. There are therefore a number of actions of ghrelin beyond appetite regulation that may be of therapeutic benefit in cachexia, but there are as yet only limited data in this area. Much further work will be needed to establish the place of ghrelin in clinical use and there are important practical problems that will need to be solved.

One major limitation of treatments based on natural hormones is the need for parenteral administration because of the large size of the molecule. It is therefore of interest that a number of small-molecule analogues are available that are orally absorbed and are currently being investigated for therapeutic potential. RC-1291 (amorelin) in particular has shown efficacy in terms of growth hormone secretion as well as appetite stimulation and weight gain in phase 1 studies(Reference Garcia and Polvino91, Reference Piccoli, Degen, MacLean, Peter, Baselgia, Larsen, Beglinger and Drewe92); the results of future trials are eagerly awaited.

Conclusion

Cachexia begins early in the course of many chronic diseases and shortens survival. It is caused by a down-regulation in appetite, which makes it resistant to long-term treatment with nutritional supplements. Appetite can be increased, however, using the natural appetite regulatory hormone ghrelin, and this pathway shows early promise in clinical trials as an appetite-stimulating and anabolic treatment. The extent to which a long-term increase in energy intake will improve the clinical features and survival of cachexia remains unknown, but the ability to achieve the former may soon be a reality, allowing this important question to be answered.

Acknowledgements

The Department is funded by a Wellcome Trust and Medical Research Council Programme Grant, an EU 6th Framework Programme grant (LSHM-CT-2003–503041) and a Biotechnology and Biological Sciences Research Council Capacity Award (B/E52708X/1) and from the NIHR Biomedical Research Centre Funding Scheme.

References

Chazot, C, Laurent, G, Charra, B, Blanc, C, VoVan, C, Jean, G, Vanel, T, Terrat, JC & Ruffet, M (2001) Malnutrition in long-term haemodialysis survivors. Nephrol Dial Transplant 16, 6169.CrossRefGoogle ScholarPubMed
Garg, AX, Blake, PG, Clark, WF, Clase, CM, Haynes, RB & Moist, LM (2001) Association between renal insufficiency and malnutrition in older adults: results from the NHANES III. Kidney Int 60, 18671874.CrossRefGoogle ScholarPubMed
Kopple, JD, Greene, T, Chumlea, WC, Hollinger, D, Maroni, BJ, Merrill, D, Scherch, LK, Schulman, G, Wang, S-R & Zimmer, GS (2000) Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57, 16881703.CrossRefGoogle ScholarPubMed
O'Sullivan, AJ, Lawson, JA, Chan, M & Kelly, JJ (2002) Body composition and energy metabolism in chronic renal insufficiency. Am J Kidney Dis 39, 369375.CrossRefGoogle ScholarPubMed
Degoulet, P, Legrain, M, Reach, I, Aime, F, Devries, C, Rojas, P & Jacobs, C (1982) Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31, 103110.CrossRefGoogle ScholarPubMed
Leavey, SF, McCullough, K, Hecking, E, Goodkin, D, Port, FK & Young, EW (2001) Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16, 23862394.CrossRefGoogle ScholarPubMed
Pifer, TB, McCullough, KP, Port, FK, Goodkin, DA, Maroni, BJ, Held, PJ & Young, EW (2002) Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62, 22382245.CrossRefGoogle ScholarPubMed
Port, FK, Ashby, VB, Dhingra, RK, Roys, EC & Wolfe, RA (2002) Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13, 10611066.CrossRefGoogle ScholarPubMed
Kalantar-Zadeh, K, Block, G, McAllister, CJ, Humphreys, MH & Kopple, JD (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80, 299307.CrossRefGoogle ScholarPubMed
Shinaberger, CS, Kilpatrick, RD, Regidor, DL, McAllister, CJ, Greenland, S, Kopple, JD & Kalantar-Zadeh, K (2006) Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 48, 3749.CrossRefGoogle ScholarPubMed
Wang, AY, Sea, MM, Tang, N, Sanderson, JE, Lui, SF, Li, PK & Woo, J (2004) Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 15, 31343143.CrossRefGoogle ScholarPubMed
Kakiya, R, Shoji, T, Tsujimoto, Y et al. (2006) Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 70, 549556.CrossRefGoogle ScholarPubMed
Maggiore, Q, Nigrelli, S, Ciccarelli, C, Grimaldi, C, Rossi, GA & Michelassi, C (1996) Nutritional and prognostic correlates of bioimpedance indexes in hemodialysis patients. Kidney Int 50, 21032108.CrossRefGoogle ScholarPubMed
Avram, MM, Sreedhara, R, Fein, P, Oo, KK, Chattopadhyay, J & Mittman, N (2001) Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters. Am J Kidney Dis 37, Suppl. 2, S77S80.CrossRefGoogle ScholarPubMed
Mittman, N, Avram, MM, Oo, KK & Chattopadhyay, J (2001) Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am J Kidney Dis 38, 13581364.CrossRefGoogle ScholarPubMed
Davos, CH, Doehner, W, Rauchhaus, M, Cicoira, M, Francis, DP, Coats, AJ, Clark, AL & Anker, SD (2003) Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 9, 2935.CrossRefGoogle ScholarPubMed
Lavie, CJ, Osman, AF, Milani, RV & Mehra, MR (2003) Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 91, 891894.CrossRefGoogle ScholarPubMed
Veloso, LG, de Oliveira, MT Jr, Munhoz, RT, Morgado, PC, Ramires, JA & Barretto, AC (2005) Repercussão nutricional na insuficiência cardíaca avançada e seu valor na avaliação prognóstica (Nutritional repercussion in advanced heart failure and its value in prognostic assessment). Arq Bras Cardiol 84, 480485.CrossRefGoogle ScholarPubMed
Anker, SD, Negassa, A, Coats, AJ, Afzal, R, Poole-Wilson, PA, Cohn, JN & Yusuf, S (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361, 10771083.CrossRefGoogle ScholarPubMed
Akashi, YJ, Springer, J & Anker, SD (2005) Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2, 198203.CrossRefGoogle ScholarPubMed
Freeman, LM & Roubenoff, R (1994) The nutrition implications of cardiac cachexia. Nutr Rev 52, 340347.CrossRefGoogle ScholarPubMed
Landbo, C, Prescott, E, Lange, P, Vestbo, J & Almdal, TP (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160, 18561861.CrossRefGoogle ScholarPubMed
Schols, AM, Broekhuizen, R, Weling-Scheepers, CA & Wouters, EF (2005) Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82, 5359.CrossRefGoogle ScholarPubMed
Chailleux, E, Laaban, J & Veale, D (2003) Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest 123, 14601466.CrossRefGoogle ScholarPubMed
Alberino, F, Gatta, A, Amodio, P, Merkel, C, Di Pascoli, L, Boffo, G & Caregaro, L (2001) Nutrition and survival in patients with liver cirrhosis. Nutrition 17, 445450.CrossRefGoogle ScholarPubMed
Escalante, A, Haas, RW & del Rincon, I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165, 16241629.CrossRefGoogle ScholarPubMed
Kremers, HM, Nicola, PJ, Crowson, CS, Ballman, KV & Gabriel, SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50, 34503457.CrossRefGoogle ScholarPubMed
Di Fiore, F, Lecleire, S, Pop, D, Rigal, O, Hamidou, H, Paillot, B, Ducrotté, P, Lerebours, E & Michel, P (2007) Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102, 25572563.CrossRefGoogle ScholarPubMed
Montgomery, RB, Goldman, B, Tangen, CM, Hussain, M, Petrylak, DP, Page, S, Klein, E & Crawford, E (2007) Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol 178, 19461951.CrossRefGoogle Scholar
Temkin, SM, Pezzullo, JC, Hellmann, M, Lee, YC & Abulafia, O (2007) Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol 30, 814.CrossRefGoogle ScholarPubMed
Barber, MD, Ross, JA & Fearon, KC (1999) Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 35, 106110.CrossRefGoogle ScholarPubMed
DeWys, WD, Begg, C, Lavin, PT et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491497.CrossRefGoogle ScholarPubMed
Whiteman, MK, Hillis, SD, Curtis, KM, McDonald, JA, Wingo, PA & Marchbanks, PA (2005) Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 14, 20092014.CrossRefGoogle ScholarPubMed
Lis, CG, Grutsch, JF, Vashi, PG & Lammersfeld, CA (2003) Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr 27, 1015.CrossRefGoogle ScholarPubMed
Stenvinkel, P, Heimburger, O, Paultre, F, Diczfalusy, U, Wang, T, Berglund, L & Jogestrand, T (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55, 18991911.CrossRefGoogle ScholarPubMed
Brown, WJ, Williams, L, Ford, JH, Ball, K & Dobson, AJ (2005) Identifying the energy gap: magnitude and determinants of 5-year weight gain in midage women. Obes Res 13, 14311441.CrossRefGoogle ScholarPubMed
Diaz, EO, Prentice, AM, Goldberg, GR, Murgatroyd, PR & Coward, WA (1992) Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. Am J Clin Nutr 56, 641655.CrossRefGoogle ScholarPubMed
Weigle, DS (1994) Appetite and the regulation of body composition. FASEB J 8, 302310.CrossRefGoogle ScholarPubMed
Zhang, Y, Proenca, R, Maffei, M, Barone, M, Leopold, L & Friedman, JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425432.CrossRefGoogle ScholarPubMed
Cano, NJ, Fouque, D, Roth, H et al. (2007) Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 18, 25832591.CrossRefGoogle Scholar
Schulze, PC, Kratzsch, J, Linke, A, Schoene, N, Adams, V, Gielen, S, Erbs, S, Moebius-Winkler, S & Schuler, G (2003) Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 5, 3340.CrossRefGoogle ScholarPubMed
Doehner, W, Pflaum, CD, Rauchhaus, M et al. (2001) Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol 145, 727735.CrossRefGoogle ScholarPubMed
Heimburger, O, Lonnqvist, F, Danielsson, A, Nordenstrom, J & Stenvinkel, P (1997) Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 8, 14231430.CrossRefGoogle Scholar
Howard, JK, Lord, GM, Clutterbuck, EJ, Ghatei, MA, Pusey, CD & Bloom, SR (1997) Plasma immunoreactive leptin concentration in end-stage renal disease. Clin Sci (Lond) 93, 119126.CrossRefGoogle ScholarPubMed
le Roux, CW, Ghatei, MA, Gibbs, JS & Bloom, SR (2005) The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart 91, 241242.CrossRefGoogle ScholarPubMed
Odamaki, M, Furuya, R, Yoneyama, T, Nishikino, M, Hibi, I, Miyaji, K & Kumagai, H (1999) Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis 33, 361368.CrossRefGoogle ScholarPubMed
Marks, DL, Ling, N & Cone, RD (2001) Role of the central melanocortin system in cachexia. Cancer Res 61, 14321438.Google ScholarPubMed
Cheung, W, Yu, PX, Little, BM, Cone, RD, Marks, DL & Mak, RH (2005) Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115, 16591665.CrossRefGoogle ScholarPubMed
Wisse, BE, Frayo, RS, Schwartz, MW & Cummings, DE (2001) Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 142, 32923301.CrossRefGoogle ScholarPubMed
Markison, S, Foster, AC, Chen, C, Brookhart, GB, Hesse, A, Hoare, SR, Fleck, BA, Brown, BT & Marks, DL (2005) The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 146, 27662773.CrossRefGoogle ScholarPubMed
Nicholson, JR, Kohler, G, Schaerer, F, Senn, C, Weyermann, P & Hofbauer, KG (2006) Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 317, 771777.CrossRefGoogle ScholarPubMed
Stanley, S, Wynne, K, McGowan, B & Bloom, S (2005) Hormonal regulation of food intake. Physiol Rev 85, 11311158.CrossRefGoogle ScholarPubMed
Wynne, K, Stanley, S, McGowan, B & Bloom, S (2005) Appetite control. J Endocrinol 184, 291318.CrossRefGoogle ScholarPubMed
Kojima, M, Hosoda, H, Date, Y, Nakazato, M, Matsuo, H & Kangawa, K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656660.CrossRefGoogle ScholarPubMed
Date, Y, Murakami, N, Kojima, M, Kuroiwa, T, Matsukura, S, Kangawa, K & Nakazato, M (2000) Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun 275, 477480.CrossRefGoogle ScholarPubMed
Arvat, E, Di Vito, L, Broglio, F, Papotti, M, Muccioli, G, Dieguez, C, Casanueva, FF, Deghenghi, R, Camanni, F & Ghigo, E (2000) Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 23, 493495.CrossRefGoogle ScholarPubMed
Kamegai, J, Tamura, H, Shimizu, T, Ishii, S, Sugihara, H & Wakabayashi, I (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50, 24382443.CrossRefGoogle ScholarPubMed
Nakazato, M, Murakami, N, Date, Y, Kojima, M, Matsuo, H, Kangawa, K & Matsukura, S (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194198.CrossRefGoogle ScholarPubMed
Shintani, M, Ogawa, Y, Ebihara, K et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50, 227232.CrossRefGoogle ScholarPubMed
Tschop, M, Smiley, DL & Heiman, ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908913.CrossRefGoogle ScholarPubMed
Wren, AM, Small, CJ, Ward, HL et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141, 43254328.CrossRefGoogle ScholarPubMed
Wren, AM, Small, CJ, Abbott, CR et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 25402547.CrossRefGoogle ScholarPubMed
Wren, AM, Seal, LJ, Cohen, MA, Brynes, AE, Frost, GS, Murphy, KG, Dhillo, WS, Ghatei, MA & Bloom, SR (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.CrossRefGoogle ScholarPubMed
Druce, MR, Neary, NM, Small, CJ, Milton, J, Monteiro, M, Patterson, M, Ghatei, MA & Bloom, SR (2005) Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes (Lond) 30, 293296.CrossRefGoogle Scholar
Cummings, DE, Weigle, DS, Frayo, RS, Breen, PA, Ma, MK, Dellinger, EP & Purnell, JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346, 16231630.CrossRefGoogle ScholarPubMed
Cummings, DE, Purnell, JQ, Frayo, RS, Schmidova, K, Wisse, BE & Weigle, DS (2002) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 17141719.CrossRefGoogle Scholar
Hataya, Y, Akamizu, T, Hosoda, H, Kanamoto, N, Moriyama, K, Kangawa, K & Nakao, K (2003) Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. Endocrinology 144, 53655371.CrossRefGoogle ScholarPubMed
Nagaya, N, Uematsu, M, Kojima, M et al. (2001) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104, 14301435.CrossRefGoogle ScholarPubMed
DeBoer, MD, Zhu, XX, Levasseur, P et al. (2007) Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148, 30043012.CrossRefGoogle Scholar
Wang, W, Andersson, M, Iresjo, BM, Lonnroth, C & Lundholm, K (2006) Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia. Int J Oncol 28, 13931400.Google ScholarPubMed
Neary, NM, Small, CJ, Wren, AM, Lee, JL, Druce, MR, Palmieri, C, Frost, GS, Ghatei, MA, Coombes, RC & Bloom, SR (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89, 28322836.CrossRefGoogle ScholarPubMed
Wynne, K, Giannitsopoulou, K, Small, CJ, Patterson, M, Frost, G, Ghatei, MA, Brown, EB, Bloom, SR & Choi, P (2005) Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 16, 21112118.CrossRefGoogle ScholarPubMed
Nagaya, N, Moriya, J, Yasumura, Y, Uematsu, M, Ono, F, Shimizu, W, Ueno, K, Kitakaze, M, Miyatake, K & Kangawa, K (2004) Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110, 36743679.CrossRefGoogle ScholarPubMed
Nagaya, N, Itoh, T, Murakami, S, Oya, H, Uematsu, M, Miyatake, K & Kangawa, K (2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 128, 11871193.CrossRefGoogle ScholarPubMed
Lin, Y, Matsumura, K, Fukuhara, M, Kagiyama, S, Fujii, K & Iida, M (2004) Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 43, 977982.CrossRefGoogle ScholarPubMed
Shinde, UA, Desai, KM, Yu, C & Gopalakrishnan, V (2005) Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channels. J Hypertens 23, 779784.CrossRefGoogle ScholarPubMed
Okumura, H, Nagaya, N, Enomoto, M, Nakagawa, E, Oya, H & Kangawa, K (2002) Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 39, 779783.CrossRefGoogle ScholarPubMed
Nagaya, N, Miyatake, K, Uematsu, M, Oya, H, Shimizu, W, Hosoda, H, Kojima, M, Nakanishi, N, Mori, H & Kangawa, K (2001) Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 86, 58545859.CrossRefGoogle ScholarPubMed
Nagaya, N, Kojima, M, Uematsu, M, Yamagishi, M, Hosoda, H, Oya, H, Hayashi, Y & Kangawa, K (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280, R1483R1487.CrossRefGoogle ScholarPubMed
Enomoto, M, Nagaya, N, Uematsu, M et al. (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 105, 431435.CrossRefGoogle ScholarPubMed
Henriques-Coelho, T, Roncon-Albuquerque, JR, Lourenco, AP, Baptista, MJ, Oliveira, SM, Brandao-Nogueira, A, Correia-Pinto, J & Leite-Moreira, AF (2006) Ghrelin reverses molecular, structural and hemodynamic alterations of the right ventricle in pulmonary hypertension. Rev Port Cardiol 25, 5563.Google ScholarPubMed
Hattori, N, Saito, T, Yagyu, T, Jiang, BH, Kitagawa, K & Inagaki, C (2001) GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab 86, 42844291.CrossRefGoogle Scholar
Dixit, VD, Schaffer, EM, Pyle, RS, Collins, GD, Sakthivel, SK, Palaniappan, R, Lillard, JW Jr & Taub, DD (2004) Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 114, 5766.CrossRefGoogle ScholarPubMed
Li, WG, Gavrila, D, Liu, X, Wang, L, Gunnlaugsson, S, Stoll, LL, McCormick, ML, Sigmund, CD, Tang, C & Weintraub, NL (2004) Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109, 22212226.CrossRefGoogle ScholarPubMed
Dembinski, A, Warzecha, Z, Ceranowicz, P, Tomaszewska, R, Stachura, J, Konturek, SJ & Konturek, PC (2003) Ghrelin attenuates the development of acute pancreatitis in rat. J Physiol Pharmacol 54, 561573.Google ScholarPubMed
Granado, M, Priego, T, Martin, AI, Villanua, MA & Lopez-Calderon, A (2005) Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2. in arthritic rats. Am J Physiol Endocrinol Metab 288, E486E492.CrossRefGoogle ScholarPubMed
Gonzalez-Rey, E, Chorny, A & Delgado, M (2006) Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130, 17071720.CrossRefGoogle Scholar
Kasimay, O, Iseri, SO, Barlas, A, Bangir, D, Yegen, C, Arbak, S & Yegen, B (2006) Ghrelin ameliorates pancreaticobiliary inflammation and associated remote organ injury in rats. Hepatol Res 36, 1119.CrossRefGoogle ScholarPubMed
Wu, R, Dong, W, Zhou, M, Zhang, F, Marini, CP, Ravikumar, TS & Wang, P (2007) Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176, 805813.CrossRefGoogle ScholarPubMed
Li, GZ, Jiang, W, Zhao, J, Pan, CS, Cao, J, Tang, CS & Chang, L (2005) Ghrelin blunted vascular calcification in vivo and in vitro in rats. Regul Pept 129, 167176.CrossRefGoogle ScholarPubMed
Garcia, JM & Polvino, WJ (2007) Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12, 594600.CrossRefGoogle ScholarPubMed
Piccoli, F, Degen, L, MacLean, C, Peter, S, Baselgia, L, Larsen, F, Beglinger, C & Drewe, J (2007) Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects. J Clin Endocrinol Metab 92, 18141820.CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1. Simplified model of homeostatic appetite control. Appetite is largely governed by the opposing actions of two populations of neurons within the hypothalamus: those releasing melanocortin (MC)-stimulating hormone (αMSH), which act via the MC3 and MC4 receptors and reduce appetite; those releasing neuropeptide Y (NPY), which act via the Y1 and Y5 receptors to increase appetite. A number of circulating hormones affect appetite largely through their action on these hypothalamic neurones. Leptin from adipose tissue reduces appetite, whereas ghrelin from the stomach increases appetite. The gastrointestinal tract also releases a number of ‘satiety’ hormones after a meal that, amongst other actions, reduce appetite; these hormones include peptide YY (PYY) and glucagon-like peptide 1 (GLP-1). , Stimulates; …, inhibits.